http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7879977-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9bf7439808d578ab8c3698f7560fe4ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6115b7f4561db088f26a575e9339fed0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-415 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-35 |
| filingDate | 2006-01-10^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2011-02-01^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68d9ab7a82d963615945f5e5ea5dbe2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41ff6149c637c143bc56adcf541aace3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac69333bff106b4347b25ba8cc0d252d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08085f41ea74fd6255b4c500c0594377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31fa18fe176cc5b21b8d23984adf732e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f9dc4d250bb090affc49bd6792f657d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dd19eeaf8ee4f6d94b6b58e1ea3eff5 |
| publicationDate | 2011-02-01^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-7879977-B2 |
| titleOfInvention | Methods and reagents for decreasing clinical reaction to allergy |
| abstract | It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by masking the site with a compound that prevents IgE binding or by altering as little as a single amino acid within the protein, most typically a hydrophobic residue towards the center of the IgE-binding epitope, to eliminate IgE binding. The method allows the protein to be altered as minimally as possible, other than-within the IgE-binding sites, while retaining the ability of the protein to activate T cells, and, in some embodiments by not significantly altering or decreasing IgG binding capacity The examples use peanut allergens to demonstrate alteration of IgE binding sites. The critical amino acids within each of the IgE binding epitopes of the peanut protein that are important to immunoglobulin binding have been determined. Substitution of even a single amino acid within each of the epitopes led to loss of IgE binding. Although the epitopes shared no common amino acid sequence motif, the hydrophobic residues located in the center of the epitope appeared to be most critical to IgE binding. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013171268-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2664624-A1 |
| priorityDate | 1998-01-31^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 209 of 209.